ClavystBio

ClavystBio is a Singapore-based venture builder and investor in life sciences, conceived by Temasek. It invests in biotechnology and medical technology companies and partners with founders on company formation, with the stated aim of translating scientific breakthroughs into companies addressing global health. Its technical interests span therapeutics development, drug discovery platforms and healthcare delivery technology.

At the investment stage, ClavystBio leads seed and Series A rounds. Beyond capital, it takes an operating role in company formation, working alongside founders rather than acting solely as a financier. The firm describes its remit as advancing Singapore's position as a global life sciences translational hub.

Geographically, ClavystBio works across Asia, Europe and the United States, while remaining anchored in Singapore. It also runs Node 1, an innovation space at Singapore Science Park that provides laboratory and office infrastructure for ventures progressing beyond incubation, alongside a venue intended to bring together academics, entrepreneurs, industry participants and investors.

The firm's stated areas of focus include biotechnology, medical technology, life sciences, therapeutics and pharmaceuticals, and healthcare. Its partnership model emphasises collaboration across that ecosystem and a mission-driven orientation towards changing treatment paradigms.